IDTs San Diego, California, Manufacturing Facility Receives ISO 14001 Certification
Integrated DNA Technologies (IDT) has announced that its San Diego, California, manufacturing facility has attained ISO 14001:2004 certification for its environmental management systems. Now, both of IDT’s US manufacturing sites (Coralville, IA and San Diego, CA) have ISO 14001 certified environmental management systems. The Coralville facility was first certified in 2012 and recertified in 2014.
In honor of the San Diego facility’s achievement, the company is launching the IDT ISO 14001 Sustainability Award, Earth Day. The contest for the inaugural award is focused on biodiversity and is open to all academic researchers in Southern California. Future awards may focus on other regions and other areas of study. The award recipient will receive $14,001 worth of Oligo Credit from IDT. Submission deadline is 15 June 2015, and the winner will be announced during a special event hosted at IDT’s San Diego facility on 18 August 2015.
Dan Dernbach, General Manager of IDT’s West Coast Operations, said attaining certification was a team effort. “ISO 14001 certification solidifies our commitment to meet the highest standard of environmental accountability. We are proud of our employees’ dedication to reducing our energy consumption and water usage while increasing our recycling efforts and our use of recyclable materials. We have also reduced the use of solvents and minimized the creation of hazardous waste.”
Dr Joseph A. Walder, IDT founder and CEO, agrees: “This certification is an important milestone for our San Diego facility. The site has grown significantly since its opening in 2005. In 2014 alone, we achieved double digit growth in both production and revenue, and increased the number of staff 20%. Attaining ISO 14001 certification while also further developing our business demonstrates our commitment to both sound environmental sustainability and responsible economic growth.”
“What better way to acknowledge the San Diego facility’s ISO 14001 achievement than to advance local research efforts at discovery in biodiversity,” said Dr Mark Behlke, IDT’s Chief Scientific Officer. “With this award, we hope to encourage and support innovative solutions that make a difference in our local communities and for our planet.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.